Beone Medicines
ONC
Beone Medicines (ONC) news
Recent news
Beone to present Herizon-GEA-01 IA2 data in 4Q 2026
Beone Biologics announced plans to present data from its Herizon-GEA-01 IA2 trial in the fourth quarter of 2026. The company has not disclosed specific details regarding the trial outcomes, but the presentation is expected to provide insights into the investigational therapy's potential role in…
AInvest Wire · 7h agoBeone's Tevimbra-Ziihera combo shows improved OS ratio
AInvest Wire · 7h agoBeone Medicines - No new safety signals identified for Ziihera and Tevimbra regimens at IA2
AInvest Wire · 7h agoBeone Medicines announces new phase 3 survival data reinforcing benefit of Ziihera-containing regimens in first-line HER2+ gastric cancer
AInvest Wire · 7h agoBeone Medicines says H1 net profit up 627.2% y/y
AInvest Wire · 5d agoLight Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.